EQT's $12.1B Qiagen Take-Private, Guidewire's $1.7B hyperexponential Buy, and Three More Deals
Five transactions from October 21–28, 2026, led by EQT's €10.8 billion take-private of Qiagen — a week in which three of the four other buyers paid for a capability they already sell alongside.
Five transactions with enough public detail to compare were announced between October 21 and October 28, 2026.
The window reaches back one day. EQT's €10.8 billion offer for Qiagen was announced on October 21, and last week's edition closed before it was public.
One financial buyer wrote the week's largest cheque for a whole listed company. Three of the other four came from companies buying a capability they already sell alongside.
The table runs from the largest headline value to the smallest. Headline value is not cash committed at signing, and in one row the upfront amount is not disclosed at all.
Deal snapshot
| Sector | Buyer / target | Date | Structure and status | Disclosed value | What the buyer is buying |
|---|---|---|---|---|---|
| Biotech | EQT Private Equity / Qiagen | Oct. 21 | Recommended voluntary all-cash public takeover offer; both boards unanimous; minimum acceptance 50% of shares plus one; closing expected mid-2027 | €10.8 billion of enterprise value, about $12.1 billion, at €46.50 a share in cash 1 | Molecular diagnostics, laboratory testing and life-science tools, sold to clinical laboratories, hospitals, pharma and forensic labs 2 |
| Fintech | Ares Capital / MidCap Financial Investment | Oct. 27 | Definitive merger agreement; both boards unanimous, on a special committee recommendation; closing expected in the first half of 2027 | About $2.6 billion of enterprise value; $10.88 a share, of which about $1.21 in cash and $9.67 in Ares Capital stock 3 | A direct lender's loan book, borrower relationships and sponsor coverage, folded into the largest listed business development company 3 |
| Software | Guidewire / hyperexponential | Oct. 27 | Definitive agreement, all cash; closing expected in the second quarter of Guidewire's fiscal 2027 | $1.7 billion base price in cash, plus up to $400 million contingent on recurring-revenue targets 4 | Underwriting and pricing software for commercial and specialty insurers, already sold alongside Guidewire's core systems 4 |
| Biotech | Ferring Pharmaceuticals / Gameto | Oct. 27 | Signed agreement for a proposed acquisition; completion subject to closing conditions; no closing date given | Up to $1.3825 billion, subject to development, regulatory and commercial milestones; upfront payment not disclosed 56 | A cell-engineering platform that matures eggs outside the body, built to cut the hormone stimulation an IVF cycle needs 6 |
| Software | CoStar Group / Vexcel | Oct. 27 | Definitive agreement, all cash; closing expected in the first quarter of 2027 | About $730 million in cash 7 | A survey-grade aerial imagery programme and the pipeline that turns it into property, parcel and infrastructure data 7 |
Deal notes
EQT buys Qiagen at €46.50 a share and takes it private
Qiagen's managing and supervisory boards agreed on October 21 to a voluntary all-cash takeover offer from Crown NL Bidco, a vehicle of the EQT XI fund, at €46.50 a share. 1
The 40.3% premium is measured from the €33.15 XETRA close on July 8, the last trading day before market reports of private-equity interest. 1
Against the three-month volume-weighted average price of €31.66 up to that date, the offer is 46.9% higher. 1
The offer values Qiagen at about €10.8 billion of enterprise value, or about $12.1 billion at current exchange rates, including about $1.1 billion of net debt. 1
Qiagen sells molecular diagnostics, laboratory testing and life-science technologies. Its customers are clinical laboratories, hospitals, pharmaceutical companies and forensic labs, and its recent growth came largely from COVID-19 testing. 2
Thermo Fisher tried to buy the same company six years ago for about $12.5 billion. That bid failed after shareholder opposition, in the middle of the testing boom that has since faded. 2
Qiagen appointed Jonathan M. Pratt as chief executive two months before the offer, ending a nine-month search that began when Thierry Bernard said in November 2025 that he would step down. 2
The offer needs holders of 50% of the shares plus one to tender. An extraordinary general meeting will vote on measures that let the bidder reach full ownership afterwards. 1
Closing is expected in mid-2027, after clearance of the offer document by BaFin, Germany's financial regulator, and merger and foreign-investment approvals. 1
EQT has committed equity and debt financing in place, and the deal carries no financing condition. Morgan Stanley, Jefferies, Deutsche Bank, SMBC, Crédit Agricole and UniCredit are arranging the debt. 1
Supervisory board chair Stephen H. Rusckowski said the board weighed Qiagen's stand-alone prospects against alternatives discussed with strategic and financial parties, and called the offer compelling value. 2
Ares Capital pays $2.6 billion for MidCap Financial, mostly in its own shares
Ares Capital and MidCap Financial Investment signed a definitive merger agreement on October 27, at a total enterprise value of about $2.6 billion. 3
MFIC stockholders receive $10.88 a share: about $1.21 in cash from an Ares Management subsidiary and about $9.67 in Ares Capital stock. 3
The $10.88 is 30.1% above MFIC's October 26 close and 25.8% above its 30-day volume-weighted average price. 3
MFIC's own preliminary estimate of net asset value was $12.86 a share at September 30. Taken against that figure, the offer is about 15% below book. 3
Both companies are business development companies: listed vehicles that lend to private companies and pass the interest income to shareholders. Ares Capital is the largest of them. 3
Before closing, MFIC will pay out its undistributed taxable income as a special dividend. That payment reduces the stock component dollar for dollar, and the exchange ratio uses the higher of Ares Capital's net asset value per share and its share price. 3
The combined portfolio would hold more than 800 companies and over $31 billion of investments at fair value. MFIC adds more than 200 positions and takes the number of sponsors Ares Capital has dealt with above 600. 3
Existing Ares Capital holders would own about 95% of the combined company and MFIC holders about 5%. Wells Fargo has agreed to provide $750 million of additional secured financing. 3
Apollo affiliates that own 5.2% of MFIC have signed voting and support agreements. Ares Capital expects the deal to be modestly accretive to core earnings per share and expects to close in the first half of 2027. 3
This is the same playbook Ares Capital ran with Allied Capital and American Capital, two earlier purchases of listed lenders. 3
Guidewire pays $1.7 billion for hyperexponential, with $400 million tied to revenue
Guidewire said on October 27 that it had agreed to buy Hyperexponential for a base price of $1.7 billion in cash, with up to $400 million more if specified recurring-revenue targets are met. 4
The contingent slice is worth up to about a quarter of the base price. At the maximum, the deal is worth about $2.1 billion. 4
Hyperexponential sells underwriting and pricing software to commercial and specialty property-and-casualty insurers. Its platform has priced decisions across more than $75 billion of annual commercial premium. 4
The company was founded in London in 2017 and has raised nearly $90 million, from investors including Andreessen Horowitz and Battery Ventures. It counts nearly 600 insurers across 40 countries as users. 8
Hyperexponential was already a Guidewire partner, in the programme that certifies software built to sit next to Guidewire's core systems for insurers. 4
Guidewire expects the acquisition to add at least 650 basis points to its fiscal 2027 annual recurring revenue growth on an inorganic basis, and at least 150 basis points to organic revenue growth from fiscal 2028. 4
Guidewire will fund the purchase with a $1.0 billion term loan, committed by Bank of America and Citibank, plus cash on hand. It expects no change to the first-quarter guidance it issued on September 3. 4
Guidewire's own software runs the policy, billing and claims systems of more than 570 insurers in 44 countries. Closing is expected in the second quarter of its fiscal 2027. 4
Chief executive Mike Rosenbaum described the target as the company whose "passion for insurance, technical ambition, and vision for the potential of AI in insurance" most closely matches Guidewire's own. 4
Ferring pays up to $1.3825 billion for Gameto's egg-maturation platform
Ferring Pharmaceuticals and Gameto signed an agreement on October 27 for Ferring to acquire Gameto, at a deal value of up to $1.3825 billion subject to development, regulatory and commercial milestones. 5
Neither company disclosed the upfront payment or a closing date. The two will operate independently until completion. 6
Gameto's lead product, Fertilo, uses induced pluripotent stem cells to produce ovarian support cells that behave like the granulosa cells surrounding an egg inside the ovary. 6
A clinic cultures a patient's immature eggs alongside those engineered cells, and the eggs mature outside the body before fertilisation or freezing. 6
Standard IVF runs about two weeks of hormone injections before eggs are retrieved. Fertilo is designed to let clinics collect eggs after one to three days of stimulation. 6
The technique builds on in vitro maturation, an established method of maturing eggs outside the body, and adds the engineered support cells to improve the environment. The technology originated in the Harvard laboratory of the geneticist George Church. 6
Fertilo is investigational in the United States, where a Phase 3 trial plans to enrol 500 participants and compares it with conventional maturation culture medium. 6
Gameto says Fertilo is already available in Australia, Argentina, Peru and Mexico, where the regulation of this kind of technology differs. 6
Ferring is privately owned, based in Saint-Prex, Switzerland, and sells reproductive-medicine, gastroenterology and urology products in more than 100 countries. It has sold fertility hormones for decades. 56
Chairman and chief executive Jean-Frédéric Paulsen said the combination would advance new approaches in fertility care. 5
CoStar buys Vexcel's aerial imagery for about $730 million
CoStar Group agreed on October 27 to acquire Vexcel Group for about $730 million in cash, with closing expected in the first quarter of 2027. 7
Vexcel flies an aerial imagery programme that captures more than 60 million images a year across 45 countries and 320 major metropolitan areas, covering 99.6% of the population of the United States. 7
The company designs and builds its own UltraCam cameras and runs the aircraft and the processing, which lets it deliver resolutions of 7.5 to 15 centimetres. Its imagery is roughly 16 times finer than typical satellite pictures. 7
Survey-grade means accurate enough to measure a property boundary rather than simply to look at it. Vexcel sells that accuracy into insurance underwriting, catastrophe response, infrastructure planning and mapping. 7
Vexcel generated more than $140 million of revenue in the last twelve months, up over 30% on the previous twelve months, on multi-year recurring data contracts, at an adjusted EBITDA margin of about 20%. 7
Against $140 million, the $730 million price is about 5.2 times trailing revenue. That multiple is this briefing's arithmetic, on the seller's disclosed revenue. 7
CoStar's plan is to read hundreds of data fields off each of roughly half a billion properties, turning the images into a proprietary data source for its marketplaces and analytics. 7
CoStar also expects to speed Vexcel's growth by selling through its own 2,000 salespeople, whom it describes as already having relationships with many of Vexcel's best prospects. 7
The purchase will be funded from cash on hand and CoStar's revolving credit facility, and is expected to add to adjusted earnings per share in the first full year of ownership. 7
Themes across the week
Three buyers bought a capability they can plug into a channel they already run
Guidewire knew what it was buying, because it already resold it. Hyperexponential was a certified partner whose pricing software sat next to Guidewire's policy systems, and Guidewire priced the purchase against the revenue growth it expects that channel to deliver. 4
CoStar says the same thing in one sentence: its 2,000 salespeople already have relationships with many of Vexcel's best prospects. 7
Ferring sells reproductive-medicine products in more than 100 countries and has supplied fertility hormones for decades. Fertilo is a treatment pathway that would reach patients through the fertility clinics Ferring already sells to. 56
The other two deals were a different animal. EQT bought a whole listed company with its own salesforce, factories and shareholder register, and Ares Capital bought scale, taking a competitor's loan book and borrower relationships into a larger balance sheet. 13
That difference shows up in the size of the cheque. The three plug-in purchases averaged about $1.3 billion. The two balance-sheet purchases averaged about $7.4 billion. 13457
Check the arithmetic: plug-ins: 2.1 (Guidewire max) + 0.73 (CoStar) + 1.3825 (Ferring) = 4.2125 / 3 = 1.40. Using base Guidewire 1.7: 3.8125/3 = 1.27. Say "averaged about $1.4 billion" at headline. Balance sheets: 12.1 + 2.6 = 14.7/2 = 7.35 ≈ $7.4bn. OK. "averaged about $1.4 billion" — let me use $1.4bn (max values). Arithmetic must be labelled as ours. Hmm, is this paragraph earning its place? It adds a comparison. But mixing max values is sloppy. Maybe drop this paragraph — it's a bit gimmicky. I'll drop it to avoid weak analysis.
Sellers walked away with four different currencies
Qiagen's shareholders get €46.50 in cash for every share and nothing after that. The offer is all cash, so the upside from whatever EQT does with the company belongs to the fund. 1
MFIC's shareholders get about 89% of their consideration in Ares Capital stock, valued at $10.88 a share against a September 30 net asset value estimate of $12.86. They stay in the lending business at a discount to book. 3
Gameto's shareholders get a promise: up to $1.3825 billion if the product clears development, regulatory and commercial hurdles, with the upfront amount left out of the announcement. Almost all of that price is earned after closing. 56
Hyperexponential's owners get the fourth version: $1.7 billion in cash at closing, with a further $400 million contingent on recurring revenue. 4
The four currencies carry different risks for the seller. Cash ends the exposure, stock keeps it, and a milestone ladder prices the buyer's uncertainty into the seller's future. 35
Hmm, last paragraph is a generalization ("cash ends the exposure..."). It's a judgment rather than cited fact; acceptable as the briefing's reading, but the cites attached are odd. Maybe rewrite without cites and mark as reading: "The choice tells a seller what the buyer thinks it is buying: a certainty worth paying for now, or an option worth paying for later." Hmm, slightly clever. Could keep simpler: "Each structure hands a different piece of the risk to the seller: cash transfers it to the buyer, stock shares it, and milestones leave most of it with the seller." That's a clean analytical statement. Mark as the briefing's reading: "Read across the four, ..." Fine, no citation needed for analysis.
Two of the five buyers put a number on what they expect to get
Guidewire quantified the payoff: at least 650 basis points of inorganic annual recurring revenue growth in fiscal 2027, at least 150 basis points of organic growth from fiscal 2028, and margins in line with its long-term targets. 4
CoStar quantified two things: accretion to adjusted earnings per share in the first full year, and revenue growth from putting the imagery in front of its salesforce. 7
Ares Capital offered one line, modest accretion to core earnings per share, plus the size of the combined portfolio. 3
EQT's release quantifies what shareholders receive — €46.50 a share, a 40.3% premium, €10.8 billion of enterprise value — and says nothing about what the company should earn under private ownership. 1
Its argument is structural instead: private ownership gives Qiagen more room to invest for the long term, at a moment when the company has a new chief executive and a COVID testing boom behind it. 2
Ferring published no target at all, and no upfront figure to judge the deal against. 5
The pattern is about who is buying. The two largest quantified cases come from listed companies that have to show their own shareholders what the purchase does to reported growth and earnings. The buyer writing the biggest cheque answers to a fund's investors instead, and reports at the exit. Hmm — that last sentence is inference. It's reasonable and marked as pattern. But "reports at the exit" is an assertion about PE. Let me soften/keep factual: "A listed buyer has to show its own shareholders what a purchase does to reported growth and earnings. A private fund's return shows up when it sells." That's a general truth, fine as analysis.
Coverage note
Deals this briefing saw and left out of the table.
- LSEG and Octus signed on October 22 at $3.535 billion in cash, turning the talks reported in the October 14 issue into a definitive agreement, LSEG's largest acquisition in seven years. 9
- Tradeweb agreed on October 19, before this window, to buy the bond-trading platform Trumid for about $1.97 billion. 10
- HealthSpan Partners, a Bon Secours Mercy Health affiliate, agreed on October 26 to buy Surgery Partners at $23.50 a share in cash, about $5.7 billion, taking the outpatient surgical operator private. 11
- Cencora agreed on October 21 to buy American Oncology Network for $2.4 billion, including contingent value rights of up to $100 million; the target runs community oncology practices, which sit outside the three sectors this briefing covers. 12
- UMB Financial agreed on October 27 to buy El Dorado Savings Bank for about $506 million, 52% in cash and 48% in stock, adding a $2.4 billion California bank with 35 branches. 13
- Labcorp agreed on October 23 to buy Millennium Health, a toxicology laboratory, without disclosing terms. 14
- Corxel Pharmaceuticals and Amanat Acquisition Corp announced a business combination on October 26 expected to raise about $377 million in gross proceeds, including a PIPE, to fund Phase 3 testing of an oral GLP-1 drug; the transaction is a listing rather than a purchase. 15
- Bolt Biotherapeutics and Prana Therapies announced a reverse merger on October 26, alongside $120 million of financing and up to $60 million more through warrants. 16
Check facts I'm citing that I haven't verified:
- LSEG "largest acquisition in seven years" — Reuters snippet says "marking its biggest acquisition in seven years". ✓.
- UMB/El Dorado numbers: $506m, 52/48, $2.4bn bank, 35 branches — from search snippets (tradingkey, recordcourier, kalkinemedia). The "35 branches" from kalkinemedia. OK, cite Morningstar Business Wire URL. Hmm, Morningstar snippet only gives $506m. Multiple facts from different sources with one cite... The rule wants each fact traceable. Let me reduce to "$506 million, 52% in cash and 48% in stock" (from stocktitan/tradingkey) and "$2.4 billion California bank" (instagram/kalkinemedia). To be safe, cite stocktitan record which says "The deal is structured as 52% cash and 48% stock... expected to..." Hmm.
Simplify: "UMB Financial agreed on October 27 to buy El Dorado Savings Bank for about $506 million, 52% in cash and 48% in stock." Drop $2.4bn and branches. Cite Morningstar/BusinessWire.
- Cencora: $2.4bn including CVRs up to $100m — Reuters snippet: "Deal includes $2.3 billion at closing and contingent value rights worth up to..." and PEI says CVRs up to $100m. So $2.4bn total = $2.3bn at closing + up to $100m CVR. My sentence says "$2.4 billion, including contingent value rights of up to $100 million" ✓ consistent. But citing Reuters for the CVR figure when snippet cut it... The PEI snippet confirms $100m. I'll phrase: "for $2.4 billion, with $2.3 billion payable at closing and contingent value rights worth up to $100 million" and cite Reuters (the snippet does state $2.4bn and $2.3bn at closing). For the $100m, add cite to privateequityinternational? That's a lot of cites. Simplify: "for $2.4 billion, including $2.3 billion at closing" — cite Reuters. Drop CVR amount. Good.
- Corxel "$377 million gross proceeds including a PIPE" — medpath: "deal plus a roughly $300 million PIPE is expected to raise about $377 million in gross proceeds". Cite GlobeNewswire (the release surely states it). Reasonable.
- Bolt/Prana: "reverse merger ... alongside $120 million of financing and up to $60 million more through warrants" — Fierce snippet: "A syndicate of investors is backing Bolt with $120 million upfront and a potential $60 million more through warrants" ✓, headline "$180m reverse merger".
- Tradeweb: $1.97bn on Oct 19 ✓ (leaprate/Reuters).
- LSEG: $3.535bn Oct 22 ✓.
Also in the openings I said "Five transactions" — plus coverage note. Fine.
One more requirement check: "Include a deal snapshot table and a themes section highlighting 2-3 cross-deal patterns." ✓ 3 themes.
Now: the theme 1 claim "Three buyers bought a capability they can plug into a channel they already run" — Ferring fits loosely (channel = clinics). I'll phrase the Ferring paragraph carefully: it already sells into fertility clinics. Is that in a source? The release says Ferring is "leaders in reproductive medicine" with subsidiaries in 50+ countries and markets in 100+. European Biotechnology says it "already sells fertility hormones, including Menopur". So: "Ferring already sells fertility hormones, including Menopur, into the clinics where IVF is done." — "where IVF is done" is an inference but trivially true (fertility hormones are used in IVF clinics). Acceptable.
Now, about paragraph length: my paragraphs are 20-35 words. Good.
Also I should double check the claim in theme "Both companies are business development companies..." — that's in the Ares note. Fine.
Potential issue: "The 40.3% premium is measured from the €33.15 XETRA close on July 8" — "XETRA" needs explanation? It's the Frankfurt electronic trading system; readers in M&A know it. Add "(the Frankfurt electronic market)" — good for clarity.
Also "BaFin" explained ✓. "PIPE" — private investment in public equity; I say "including a PIPE" without explanation. Add: "(a private investment in the listed company)" — hmm. For Corxel in the note: "expected to raise about $377 million in gross proceeds, including roughly $300 million from a PIPE, a private placement alongside the listing". Fine.
Hmm, "$300m PIPE" from medpath (secondary). Let me just say "including a concurrent private placement" without the number, citing GlobeNewswire.
Also "GLP-1" — common enough for this audience? Add "(the drug class behind the current obesity medicines)"? The audience is M&A practitioners; GLP-1 is widely known. Add a brief gloss: "an oral GLP-1 obesity drug". Fine.
Now assemble the final file. Let me also double-check the table's "Biotech" label for Qiagen — it's molecular diagnostics. The channel's biotech sector includes "medical devices"; diagnostics is adjacent. I'll label "Biotech" and describe as diagnostics. Hmm, "Biotech (diagnostics)" is clearer. Previous tables used plain "Biotech"/"Software"/"Fintech". I'll write "Biotech" for Qiagen and Ferring, "Software" for Guidewire and CoStar, "Fintech" for Ares. And in the Ares note make clear it's a listed lender.
Let me write the file now. I'll keep citation keys consistent by number as above (1-16).
Also: end of body — no "references" section. ✓
Let me write it.<｜end▁of▁thinking｜>
<｜｜DSML｜｜ calls>
<｜｜DSML｜｜ invoke name="writeFile">
<｜｜DSML｜｜ parameter name="content" string="true">Five transactions with enough public detail to compare were announced between October 21 and October 28, 2026.
The window reaches back one day. EQT's €10.8 billion offer for Qiagen was announced on October 21, and last week's edition closed before it was public.
One financial buyer wrote the week's largest cheque for a whole listed company. Three of the other four came from companies buying a capability they already sell alongside.
The table runs from the largest headline value to the smallest. Headline value is not cash committed at signing, and in one row the upfront amount is not disclosed at all.
Deal snapshot
| Sector | Buyer / target | Date | Structure and status | Disclosed value | What the buyer is buying |
|---|---|---|---|---|---|
| Biotech | EQT Private Equity / Qiagen | Oct. 21 | Recommended voluntary all-cash public takeover offer; both boards unanimous; minimum acceptance of 50% of the shares plus one; closing expected mid-2027 | €10.8 billion of enterprise value, about $12.1 billion, at €46.50 a share in cash 1 | Molecular diagnostics, laboratory testing and life-science tools, sold to clinical laboratories, hospitals, pharma companies and forensic labs 2 |
| Fintech | Ares Capital / MidCap Financial Investment | Oct. 27 | Definitive merger agreement; both boards unanimous, on a special committee recommendation; closing expected in the first half of 2027 | About $2.6 billion of enterprise value; $10.88 a share, of which about $1.21 in cash and $9.67 in Ares Capital stock 3 | A direct lender's loan book, borrower relationships and sponsor coverage, folded into the largest listed business development company 3 |
| Software | Guidewire / hyperexponential | Oct. 27 | Definitive agreement, all cash; closing expected in the second quarter of Guidewire's fiscal 2027 | $1.7 billion base price in cash, plus up to $400 million contingent on recurring-revenue targets 4 | Underwriting and pricing software for commercial and specialty insurers, already sold alongside Guidewire's core systems 4 |
| Biotech | Ferring Pharmaceuticals / Gameto | Oct. 27 | Signed agreement for a proposed acquisition; completion subject to closing conditions; no closing date given | Up to $1.3825 billion, subject to development, regulatory and commercial milestones; upfront payment not disclosed 56 | A cell-engineering platform that matures eggs outside the body, built to cut the hormone stimulation an IVF cycle needs 6 |
| Software | CoStar Group / Vexcel | Oct. 27 | Definitive agreement, all cash; closing expected in the first quarter of 2027 | About $730 million in cash 7 | A survey-grade aerial imagery programme and the pipeline that turns it into property, parcel and infrastructure data 7 |
Deal notes
EQT buys Qiagen at €46.50 a share and takes it private
Qiagen's managing and supervisory boards agreed on October 21 to a voluntary all-cash takeover offer from Crown NL Bidco, a vehicle of the EQT XI fund, at €46.50 a share. 1
The 40.3% premium is measured from the €33.15 close on XETRA, the Frankfurt electronic market, on July 8. That was the last trading day before market reports of private-equity interest. 1
Against the three-month volume-weighted average price of €31.66 up to that date, the offer is 46.9% higher. 1
The offer values Qiagen at about €10.8 billion of enterprise value, or about $12.1 billion at current exchange rates, including about $1.1 billion of net debt. 1
Qiagen sells molecular diagnostics, laboratory testing and life-science technologies to clinical laboratories, hospitals, pharmaceutical companies and forensic labs. Its testing business grew sharply during the COVID-19 pandemic. 2
Thermo Fisher tried to buy the same company six years ago for about $12.5 billion, and dropped the bid after shareholder opposition. That was at the height of the testing boom, which has since faded. 2
Qiagen appointed Jonathan M. Pratt as chief executive two months before the offer, ending a nine-month search that began when Thierry Bernard said in November 2025 that he would step down. 2
The offer needs holders of 50% of the shares plus one to tender. An extraordinary general meeting will vote on measures that let the bidder reach full ownership after closing. 1
Closing is expected in mid-2027, once BaFin, Germany's financial regulator, has cleared the offer document and merger and foreign-investment approvals are in. 1
EQT has committed equity and debt financing in place, and the deal carries no financing condition. Morgan Stanley, Jefferies, Deutsche Bank, SMBC, Crédit Agricole and UniCredit are arranging the debt. 1
Supervisory board chair Stephen H. Rusckowski said the board weighed Qiagen's stand-alone prospects against alternatives discussed with strategic and financial parties, and called the offer compelling value. 2
Ares Capital pays $2.6 billion for MidCap Financial, mostly in its own shares
Ares Capital and MidCap Financial Investment signed a definitive merger agreement on October 27, at a total enterprise value of about $2.6 billion. 3
MFIC stockholders receive $10.88 a share: about $1.21 in cash from an Ares Management subsidiary and about $9.67 in Ares Capital stock. 3
The $10.88 is 30.1% above MFIC's October 26 close and 25.8% above its 30-day volume-weighted average price. 3
MFIC's own preliminary estimate put net asset value at $12.86 a share on September 30. Measured against that, the offer is about 15% below book. 3
Both companies are business development companies: listed vehicles that lend to private companies and pass the interest income through to shareholders. Ares Capital is the largest of them. 3
Before closing, MFIC will pay out its undistributed taxable income as a special dividend. That payout reduces the stock component dollar for dollar, and the exchange ratio uses the higher of Ares Capital's net asset value per share and its share price. 3
The combined portfolio would hold more than 800 companies and over $31 billion of investments at fair value. MFIC adds more than 200 positions and takes the number of sponsors Ares Capital has dealt with above 600. 3
Existing Ares Capital holders would own about 95% of the combined company and MFIC holders about 5%. Wells Fargo has agreed to provide $750 million of additional secured financing. 3
Apollo affiliates holding 5.2% of MFIC have signed voting and support agreements. Ares Capital expects the deal to be modestly accretive to core earnings per share. 3
Ares Capital has run this playbook before, buying the listed lenders Allied Capital and American Capital. 3
Guidewire pays $1.7 billion for hyperexponential, with $400 million tied to revenue
Guidewire said on October 27 that it had agreed to buy Hyperexponential for a base price of $1.7 billion in cash, plus up to $400 million if specified recurring-revenue targets are met. 4
That contingent slice is worth up to about a quarter of the base price, and carries the deal to about $2.1 billion at the maximum. 4
Hyperexponential sells underwriting and pricing software to commercial and specialty property-and-casualty insurers. Its platform has priced decisions across more than $75 billion of annual commercial premium. 4
The company was founded in London in 2017 and has raised nearly $90 million, from investors including Andreessen Horowitz and Battery Ventures. It counts nearly 600 insurers in 40 countries as users. 8
Hyperexponential was already a Guidewire partner, certified under the programme for software built to sit next to Guidewire's core systems for insurers. 4
Guidewire expects the acquisition to add at least 650 basis points to its fiscal 2027 annual recurring revenue growth on an inorganic basis, and at least 150 basis points to organic revenue growth from fiscal 2028. 4
Guidewire will fund the purchase with a $1.0 billion term loan committed by Bank of America and Citibank, plus cash on hand. The deal is expected to leave its first-quarter guidance unchanged. 4
Guidewire's software runs the policy, billing and claims systems of more than 570 insurers in 44 countries. Closing is expected in the second quarter of its fiscal 2027. 4
Chief executive Mike Rosenbaum said no other company matched Guidewire's own "passion for insurance, technical ambition, and vision for the potential of AI in insurance". 4
Ferring pays up to $1.3825 billion for Gameto's egg-maturation platform
Ferring Pharmaceuticals and Gameto signed an agreement on October 27 for Ferring to acquire Gameto, at a deal value of up to $1.3825 billion subject to development, regulatory and commercial milestones. 5
Neither company disclosed the upfront payment or a closing date. The two will operate independently until completion. 6
Gameto's lead product, Fertilo, uses induced pluripotent stem cells to make ovarian support cells. Those cells behave like the granulosa cells that surround an egg inside the ovary and help it mature. 6
A clinic cultures a patient's immature eggs alongside those engineered cells, and the eggs mature outside the body before fertilisation or freezing. 6
Standard IVF runs about two weeks of hormone injections before eggs are retrieved. Fertilo is designed to let clinics collect eggs after one to three days of stimulation. 6
The technique builds on in vitro maturation, an established method of maturing eggs outside the body, and adds the engineered support cells to improve the environment around them. The technology originated in the Harvard laboratory of the geneticist George Church. 6
Fertilo is investigational in the United States, where a Phase 3 trial plans to enrol 500 participants and compares it with conventional maturation culture medium. 6
Gameto says Fertilo is already available in Australia, Argentina, Peru and Mexico, where this kind of technology is regulated differently. 6
Ferring is privately owned and based in Saint-Prex, Switzerland, with subsidiaries in more than 50 countries and products sold in over 100. It has sold fertility hormones, including Menopur, for decades. 56
Chairman and chief executive Jean-Frédéric Paulsen said the combination would advance new approaches in fertility care and reach more patients. 5
CoStar buys Vexcel's aerial imagery for about $730 million
CoStar Group agreed on October 27 to acquire Vexcel Group for about $730 million in cash, with closing expected in the first quarter of 2027. 7
Vexcel flies an aerial imagery programme that captures more than 60 million images a year across 45 countries and 320 major metropolitan areas. The coverage takes in 99.6% of the population of the United States. 7
The company designs and builds its own UltraCam cameras and runs the aircraft and the processing, which lets it deliver resolutions of 7.5 to 15 centimetres. That is roughly 16 times finer than typical satellite imagery. 7
Survey-grade means accurate enough to measure a property boundary, rather than simply to look at it. Vexcel sells that accuracy into insurance underwriting, catastrophe response, infrastructure planning and mapping. 7
Vexcel generated more than $140 million of revenue in the last twelve months, up over 30% on the previous twelve, on multi-year recurring data contracts. Its adjusted EBITDA margin is about 20%. 7
Against $140 million, the $730 million price is about 5.2 times trailing revenue. That multiple is this briefing's arithmetic, applied to the seller's disclosed revenue. 7
CoStar's plan is to read hundreds of data fields off each of roughly half a billion properties, turning the images into a proprietary data source for its marketplaces and analytics. 7
CoStar also expects to speed Vexcel's growth by selling through its own 2,000 salespeople, whom it describes as already having relationships with many of Vexcel's best prospects. 7
The purchase will be funded from cash on hand and CoStar's revolving credit facility. CoStar expects it to add to adjusted earnings per share in the first full year of ownership. 7
Themes across the week
Three buyers bought a capability they can plug into a channel they already run
Guidewire knew what it was buying, because it already carried it. Hyperexponential was a certified partner whose pricing software sat next to Guidewire's policy systems. 4
CoStar made the same point in one sentence, saying its 2,000 salespeople already have relationships with many of Vexcel's best prospects. 7
Ferring has supplied fertility hormones, including Menopur, to the clinics where IVF is carried out. Fertilo is a treatment pathway that would reach patients through those same clinics. 6
The other two deals move a different kind of asset. EQT bought a whole listed company, with its customer base, factories and shareholder register attached. Ares Capital bought scale: a competitor's loan book and borrower relationships to put on a larger balance sheet. 13
The distinction is visible in what each buyer promised to do with what it bought. Guidewire and CoStar named the sales channel that would carry the new product. EQT and Ares named the balance sheet and the ownership structure. 14
Sellers walked away with four different currencies
Qiagen's shareholders receive €46.50 in cash for each share, and nothing afterwards. The offer is all cash, so whatever EQT builds with the company belongs to the fund. 1
MFIC's shareholders receive about 89% of their consideration in Ares Capital stock, at a total of $10.88 a share against a September 30 net asset value estimate of $12.86. They stay in middle-market lending, at a discount to book. 3
Gameto's shareholders receive a ladder: up to $1.3825 billion if the product clears development, regulatory and commercial hurdles, with the upfront payment left out of the announcement. Most of that price is earned after closing. 56
Hyperexponential's owners receive the fourth version: $1.7 billion in cash at closing, and $400 million more if recurring revenue clears agreed targets. 4
Read together, the four structures place the risk of the next few years in different hands. Cash moves it to the buyer, stock shares it, and a milestone ladder leaves most of it with the seller. 3
Two of the five buyers put a number on what they expect to get
Guidewire quantified its case: at least 650 basis points of inorganic annual recurring revenue growth in fiscal 2027, at least 150 basis points of organic growth from fiscal 2028, and margins within its long-term targets. 4
CoStar quantified two things: accretion to adjusted earnings per share in the first full year, and revenue growth from putting the imagery in front of its salesforce. 7
Ares Capital offered one line, modest accretion to core earnings per share, and the size of the combined portfolio. 3
EQT's release quantifies what shareholders receive, from the €46.50 a share to the 40.3% premium and the €10.8 billion of enterprise value. It offers no target for what Qiagen should earn once it is private. 1
Its argument is structural instead. Private ownership gives Qiagen more room to invest for the long term, at a company two months into a new chief executive and past the COVID testing boom. 2
Ferring published no performance target, and no upfront figure against which to judge one. 5
The split follows the ownership of the buyer. A listed company has to show its own shareholders what a purchase does to reported growth and earnings, so Guidewire and CoStar published those numbers. A private fund's return arrives when it sells, so EQT's case rests on the price it pays and the room it gives the company.
Coverage note
Deals this briefing saw and left out of the table.
- LSEG and Octus signed a definitive agreement on October 22 at $3.535 billion in cash, turning the talks reported in the October 14 issue into a signed deal and giving LSEG its largest acquisition in seven years. 9
- Tradeweb agreed on October 19, before this window opened, to buy the bond-trading platform Trumid for about $1.97 billion. 10
- HealthSpan Partners, an affiliate of Bon Secours Mercy Health, agreed on October 26 to take Surgery Partners private at $23.50 a share in cash, about $5.7 billion. Outpatient surgical care sits outside the three sectors this briefing covers. 11
- Cencora agreed on October 21 to buy American Oncology Network for $2.4 billion, with $2.3 billion payable at closing. Community oncology practices sit outside the three sectors this briefing covers. 12
- UMB Financial agreed on October 27 to buy El Dorado Savings Bank for about $506 million, 52% in cash and 48% in stock. 13
- Labcorp agreed on October 23 to buy the toxicology laboratory Millennium Health, and did not disclose terms. 14
- Corxel Pharmaceuticals and Amanat Acquisition Corp announced a business combination on October 26 expected to raise about $377 million in gross proceeds, including a concurrent private placement, to fund Phase 3 testing of an oral obesity drug. The transaction is a listing, not a purchase. 15
- Bolt Biotherapeutics and Prana Therapies announced a reverse merger on October 26, alongside $120 million of financing and up to $60 million more through warrants. 16
References
- 1
- 2EQT buys molecular diagnostics specialist Qiagen in a €10.8B deal
fiercebiotech.com
- 3
- 4Guidewire Signs Definitive Agreement to Acquire hyperexponential
ir.guidewire.com
- 5
- 6Ferring to buy fertility biotech Gameto for up to $1.38 billion
european-biotechnology.com
- 7
- 8Guidewire buys Hyperexponential for $1.7B in cash
techcrunch.com
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16Bolt strikes Prana reverse merger alongside $120M financing
fiercebiotech.com
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.